#ASCO25: Immatics reports more early-stage data for melanoma cell therapy with pivotal trial underway
Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started. At an average follow-up of 14.4 months, the ...
Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.
At an average follow-up of 14.4 months, the ...
